65,437 trials
Myopia
Primary: Monocular Corrected Distance Visual Acuity (VA) — -0.01; -0.02 logMAR
Achilles Tendon Pain
Primary: Central Sensitization — 463.5; 383.6; 425.7; 358.0 kilopascal — p=0.44
Moderate to Severe Plaque-type Psoriasis
Primary: Number of Participants With PASI 90 Response at Week 32 — 93; 105 participants — p=0.087
Stroke
Primary: Percentage of Participants With a rtPA Protocol Violation — 7; 0 Participants
Heartburn · Gastroesophageal Reflux Disease
Primary: Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment — 32.67; 51.72 percentage of days — p=0.057
Hyperlipidemia
Primary: Number of Participants Who Had One or More Adverse Events (AE) and Serious Adverse Events (SAE) — 130; 26 Participants
Osteopenia
Primary: Percent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius — -1.16; 0.16; -1.03; -1.03 percent change
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Castration-resistant Prostate Cancer · Stage IV Prostate Cancer
Primary: Change in PSA Level — -1.19; -1.59 log ratio — p=<0.10
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio
Pesticide Poisoning
Primary: Incidence of Pesticide Self-poisoning — 611; 641 Participants
Overactive Bladder · Urgency Urinary Symptoms · Urgency Incontinence
Primary: Change From Baseline in Frequency of Any Voiding or Incontinence Episodes Associated With At Least a Moderate Sensation of Urgency at 12 Weeks. — -1.06; -0.86 episodes…
Agitation
Primary: Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. — -11.0; -11.5 score on a scale — p=>0.05
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE — 0; 0; 0; 0 Participants
Respiratory Muscles · Breathing Exercises
Primary: Diaphragm Electromyography — 60; 55 %max